BioCryst director granted 1,262 shares as retainer

BIOCRYST PHARMACEUTICALS INC director Jill C. Milne received a stock grant as part of her board compensation.

Rhea-AI Filing Summary

BIOCRYST PHARMACEUTICALS INC director Jill C. Milne received a stock grant as part of her board compensation. On May 29, 2026, she acquired 1,262 shares of common stock valued at $8.91 per share. The filing states these shares were issued in lieu of a quarterly cash board member retainer of $11,250.

After this award, Milne directly holds 16,644 shares of BioCryst common stock. This is a routine, non-market transaction reflecting compensation paid in equity instead of cash, rather than an open-market purchase or sale.

Insights

Equity compensation analyst

Routine equity retainer replaces cash for board service.

Director Jill C. Milne received 1,262 shares of BioCryst common stock at $8.91 per share. The footnote explains this was issued instead of a quarterly cash board retainer of $11,250, so it functions as standard equity compensation.

This is a non-market acquisition coded as a grant (A), not an open-market buy. Following the transaction, Milne holds 16,644 shares directly. The event is routine, small in scale, and does not, by itself, change the broader investment picture for BioCryst.

Insider Trade Summary

Grant/Award: 1,262 shares

Grant/Award 1 txn

Insider Milne Jill C.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,262	$8.91	$11K

Holdings After Transaction: Common Stock — 16,644 shares (Direct)

Footnotes (1)

1. F1. Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $11,250.

Key Figures

Shares granted: 1,262 shares Grant price: $8.91 per share Cash retainer replaced: $11,250 +1 more

4 metrics

Shares granted 1,262 shares Common stock grant on May 29, 2026

Grant price $8.91 per share Value used for stock retainer

Cash retainer replaced $11,250 Quarterly board member retainer paid in stock

Holdings after grant 16,644 shares Total direct BioCryst shares held by Milne after transaction

Key Terms

Form 4, Grant, award, or other acquisition, quarterly cash Board Member retainer, Common Stock

4 terms

Form 4 regulatory

"This Form 4 shows a compensation grant, not an open‑market purchase."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Grant, award, or other acquisition financial

"Code A identifies it as a grant or award, and the footnote explains the 1,262 shares."

quarterly cash Board Member retainer financial

"Shares of Common Stock issued ... in lieu of 100% of the quarterly cash Board Member retainer of $11,250."

Common Stock financial

"She acquired 1,262 shares of common stock valued at $8.91 per share."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BioCryst (BCRX) director Jill C. Milne report in this Form 4?

Jill C. Milne reported receiving 1,262 shares of BioCryst common stock. The shares were granted as part of her board compensation rather than bought on the open market, and increased her direct holdings to 16,644 shares after the transaction.

Was the BioCryst (BCRX) Form 4 transaction an insider stock purchase or a compensation grant?

The Form 4 shows a compensation grant, not an open‑market purchase. Code A identifies it as a grant or award, and the footnote explains the 1,262 shares replaced a quarterly cash board retainer of $11,250 for Jill C. Milne.

How many BioCryst (BCRX) shares does Jill C. Milne hold after this Form 4 transaction?

After receiving the stock award, Jill C. Milne directly holds 16,644 shares of BioCryst common stock. This total includes the 1,262 shares granted in lieu of her quarterly cash board retainer, as disclosed in the Form 4 filing.

What is the implied value of the BioCryst (BCRX) stock grant reported by Jill C. Milne?

The grant covers 1,262 shares valued at $8.91 per share, aligning with a quarterly board retainer of $11,250. The filing states these shares were issued entirely instead of the cash retainer, indicating a typical equity-based compensation arrangement.

Does Jill C. Milne’s BioCryst (BCRX) Form 4 indicate any stock sales?

The Form 4 does not report any stock sales. It shows a single acquisition coded as A, representing a grant or award of 1,262 shares received as board compensation in place of a cash retainer, with no disposal transactions listed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 04:16 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Milne Jill C.

(Last) (First) (Middle)

4505 EMPEROR BLVD

SUITE 200

(Street)

DURHAM NORTH CAROLINA 27703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/29/2026		A		1,262(1)	A	$8.91	16,644	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $11,250.

	/s/ Alane P. Barnes, by power of attorney	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)